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Graft versus host disease (GvHD) caused by alloreactive donor 
lymphocytes is a fatal complication of hematopoietic stem cell transplant 
(HSCT). Myeloablative conditioning regimen, consisting of chemotherapy and/or 
radiation, given prior to HSCT can cause tissue damage. This non-specific tissue 
damage triggers cross-presentation of alloantigens to the donor immune cells, 
causing recruitment of leukocytes and production of inflammatory cytokines. 
Targeting this inflammation without affecting the anti -leukemia effects of HSCT, 
continues to be one of the biggest challenge in finding a therapy for GvHD. 
Bilirubin is a tetrapyrrole pigment, found in the blood, with natural anti -oxidative 
and anti-inflammatory properties. Using mouse models of various inflammatory 
diseases, studies by our collaborating investigators have shown that, water-
soluble PEGylated bilirubin nanoparticles (BRNP) selectively accumulate at the 
site of inflammation and prevent further tissue damage through scavenging 
reactive oxygen species. Therefore, we hypothesized that BRNP treatment  after 
myeloablative conditioning regimen can reduce clinical symptoms of GvHD by 
abating the initial tissue damage in HSCT. We investigated the therapeutic 
efficacy of BRNP using murine GvHD model. Sublethally irradiated recipient 
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mice (Balb/cJ) were infused with 5x106 bone marrow cells and 5x106 splenic 
cells from MHC-mismatched donor mice (C57/B6J) on day 1, with or without 
BRNP (10 mg/kg) on days 0-4. Clinical GvHD symptoms were monitored for 60 
days, and mice were scored for fur, skin, posture, activity, and weight change. 
Untreated recipient mice (n=10) developed significantly worse GvHD (median 
GvHD score=3.4) compared to BRNP treated recipient mice (n=10, median 
GvHD score=0.3) (p=0.0003, Mann Whitney U Test). This translated into 
significantly better survival of BRNP treated mice with day 60 survival of 100% 
as compared to the untreated recipient with day 60 survival of 20% (p=0.0001, 
Log-rank (Mantel-Cox) Test). Histological analyses on day 8 post-
transplantation, showed significantly lowered GvHD associated damage in liver, 
lung, skin, and gut, in BRNP treated mice as compared with untreated mice. In 
summary, we show that prophylactic treatment with BRNP can reduce clinical 
and pathological GvHD symptoms and thereby improve survival in mice. In 
future, we plan to investigate a treatment model of BRNP in relieving the clinical 
and pathological symptoms of GvHD. We also plan to explore the potential of 
BRNP as a drug conjugate for GvHD treatment.   
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Chapter 1- Introduction 
1.1 Hematopoietic Stem Cell Transplantation 
1.1.1 Hematological Malignancies 
Hematological malignancies, also commonly known as blood cancers, 
encompass all of cancer subtypes that affect the development and function of 
various blood cells. Blood cancers can be divided into three broad categories: 
Leukemia- originates in cells found in the blood and the bone marrow; 
Lymphoma- originates in the cells found in the lymph nodes; Myeloma- affects 
the production and functioning of antibody producing plasma cells. Together, the 
three categories of blood cancer, are responsible for approximately 10% of 
cancer related deaths in the United States every year  (1).  
Depending on patient’s age, health, and stage and type of blood cancer, 
physician recommends specific treatment options or their combination. The first 
line of therapy recommendation for leukemia patients is usually chemotherapy, 
which targets the rapidly dividing cancer cells. Acute myeloid leukemia (AML) is 
the most common subtype, occurring in almost one-third of the adult patients of 
leukemia (1). According to recent statistics by the American Cancer Society, 
approximately 90% of patients with an AML subtype- acute promyelocytic 
leukemia (APL) and 67% of patients with other subtypes of AML, go into 
remission after chemotherapy induction. Despite the high remission rates, recent 
reports by the National Cancer Institute show that the overall 5 -year survival 
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rates of all AML patients are the lowest among other leukemia subtypes at 
28.3%.  
Hematopoietic stem cells (HSCs) are unique, self -renewing stem cells that 
are also capable of differentiating into all lineages of cells that comprise the 
blood- in a process called hematopoiesis. Hematopoiesis starts during 
embryonic development and continues into adulthood. Over the last fifty years, 
there has been an exponential increase in our knowledge on the biology of HSCs 
(2). This breakthrough has led to development of hematopoietic stem cell 
transplantation (HSCT) as potentially curative therapy for various hematological 
disorders, especially blood cancers. In fact, five-year survival rates for leukemia 
in United States, have risen from 14% in the 1960 to 65% in 2014. Among the 
total number of allogeneic HSCTs performed around the world, about one-third 
are indicated for AML patients (3). According to 2006-2016 statistics by Center 
for International Blood and Marrow Transplant Research (CIBMTR), among 
approximately 13,000 AML patients, those who received stem cell transplant 
from their sibling as donor, had survival rates between 20-55% depending on 
the stage of diagnosis (early, intermediate, or late). These statis tics show that 
HSCT offers long-term survival, especially for patients with AML. However, 
despite a large number of patients responding to therapy, a majority of the 
leukemia patients who do achieve complete remission, go on to relapse (4) or 
develop complications such as organ failure, infections, and graft versus host 
disease (5). 
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1.1.2 Hematopoietic Stem Cell Transplantation 
Human hematopoietic system comprises of all the cell types that 
constitute the blood, bone marrow, and the lymphatic system. Hematopoietic 
stem cell transplantation is one of the most important  and potentially curative 
therapy for leukemia and other hematological malignancies. Depending on the 
disease condition, recommended HSCT can be either autologous, syngeneic, or 
allogeneic.  
In autologous HSCT, the donor is the patient themselves and it is indicated 
for various hematological disorders, as well as cancers. Autologous HSCT is 
used to reconstitute hematopoietic system for cancer patients who are given 
high-dose chemotherapy and/or radiation. It is recommended as treatment 
modality for multiple myeloma, Non-Hodgkin’s lymphoma, Hodgkin’s disease, 
acute myeloid leukemia, neuroblastoma, and ovarian cancer (6). It is also 
recommended for diseases that do not require the anti-tumor (also known as 
graft versus leukemia (GvL) effect) benefits of transplant such as aplastic 
anemia and bone marrow diseases, or where tumor response to chemotherapy 
is high, such as germ cell tumors (ovarian cancer and testicular cancer) (7).  
Syngeneic HSCT is similar to autologous HSCT except that the donor is patient’s 
twin/triplet. While there is no development of graft versus host disease  in 
syngeneic HSCT, the anti-cancer benefits are limited to high-dose chemotherapy 
(8).  
In allogeneic HSCT, the donor is not the patient, but a matched or 
mismatched donor. Allogeneic HSCT is indicated for acute myeloid leukemia, 
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acute lymphoblastic leukemia, chronic myeloid leukemia, relapsed and 
refractory Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, relapsed 
and refractory multiple myeloma, and some hematological disorders such as 
sickle-cell anemia and Wiskott–Aldrich syndrome. While allogeneic transplant 
has high GvL activity, it is often accompanied by inflammation in host tissue due 
to donor T-cell alloreactivity in a complication known as graft versus host 
disease (GvHD)   
Allogeneic HSCT was first attempted in the 1960s, a few years after 
human leukocyte antigen (HLA) typing was first discovered (9).The first step in 
allogeneic HSCT is to find a human leukocyte antigen-matched donor. HLA is a 
gene system that encodes for major histocompatibility complex (MHC) proteins. 
The main function of the MHC protein is to present antigen in the form of peptides 
to the surveilling immune cells. The cytotoxic T-cells recognize MHC together 
with the antigen peptide, in a process known as MHC-restriction. MHC proteins 
are highly polymorphic, however one individual can have, at most,  12 different 
MHC alleles (10). High-resolution HLA-typing is employed to identify a matched 
donor. HLA-A, -B, and –C genes under Class I HLA encode for MHC Class I 
protein that is expressed on almost all the nucleated cells in the body. Whereas, 
HLA-DP, -DQ, and –DR encode for MHC Class II protein that are expressed only 
on professional antigen presenting cells such as the dendritic cells, B -cells, and 
monocytes (11). HLA-typing is done for HLA-A, -B, -C and -DRB1 (encodes HLA-
DR β-chain) to find an 8/8 match (a complete match) or a 7/8 match (12). The 
allelic diversity in HLA genes across population, makes it difficult to find a 
complete match, especially for the minority ethnicities in USA such as the 
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African-Americans (19% likelihood for 8/8 match), Africans (16% likelihood for 
8/8 match), as compared to White Europeans (75% likelihood for 8/8 match) 
according to the 2014 statistics (13).  
After identifying a matched donor, the patient goes through myeloablative 
conditioning regimen, which consists of chemotherapy and/or radiation therapy. 
Conditioning regimen is given to induce immunosuppression by eliminating all 
the patient immune cells including any leukemia cells. Meanwhile, donor 
peripheral blood or bone marrow is collected and processed to obtain HSCs, 
which are then transplanted to the recipient. Once transplanted, donor HSCs 
have two major functions- firstly, to kill any remnant leukemia cells in the 
patient’s body or the GvL effect, and secondly, to reconstitute the hematopoietic 
system of the patient who has undergone conditioning regimen.  
 1.2 Graft Versus Host Disease  
Allogenic HSCT however, comes with a debilitating side-effect of acute or 
chronic graft versus host disease. GvHD is a state of immunological disarray 
caused by the donor immune system which results in inflammation and tissue 
damage to the host. Since 2005, NIH recommended classification into acute or 
chronic GvHD is based on the time of onset of GvHD and the symptoms (14). 
Typically, acute GvHD manifests as skin rash, increased blood bilirubin levels, 
gastrointestinal tract damage leading to nausea, vomiting, diarrhea, and 
anorexia (15). It is one of the leading cause of mortality, and some of the 
symptoms manifest among most patients that receive allogeneic HSCT (16). It 
affects approximately 30-50% and severe acute GvHD occurs in approximately 
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14%, of the patients that receive allogeneic transplant f rom an HLA-matched 
donor (11, 15). The current globally immunosuppressive therapies are effective 
in treating the symptoms, but may interfere with the GvL effect of allogeneic 
HSCT, thereby not reducing post-transplantation mortality (17). Therefore, there 
is a growing need to control the potentially lethal effects of GvHD without 
affecting GvL activity. 
1.2.1 GvHD Signaling Cascade  
The process of GvHD development starts with the administration of 
conditioning regimen. Conditioning regimen consists of chemotherapy and/or 
radiation, which are known to trigger non-specific tissue damage, especially in 
the gastrointestinal (GI) tract. This damage leads to release of danger signals, 
such as, pro-inflammatory cytokines (TNF, IL-1, and IL-6 (18)), chemokines and 
chemokine receptors (19), by the host tissues, and increased expression of co-
stimulatory molecules on host APCs (11). Specifically, GI injury due to 
conditioning regimen causes systemic release of commensal gut bacteria and  
subsequent increase in lipopolysaccharide (LPS) and pathogen associated 
molecular proteins (PAMPs). This increase in danger signals, augments antigen 
presentation by host APC resulting in strong activation, proliferation, and 
differentiation of donor T-cells that play one of the most important role in GvHD-
related morbidity in leukemia patients (20). The release of danger signals also 
causes innate immune cell activation which ultimately results in increased 
production of pro-inflammatory cytokines and tissue inflammation (17). GvHD 
manifests as skin rash and progresses towards other body organs, mainly, lung, 
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liver, gut, and skin. Therefore, targeted treatment, as opposed to global 
immunosuppression, against this host inflammation and non-specific tissue 
damage caused by conditioning regimen could potentially reduce GvHD while 
maintaining the GvL activity. 
1.2.2 Alloreactivity in Graft versus Host Disease 
GvHD is largely mediated by alloreactive donor T-cells. During T-cell 
development in thymus, immature T-cells undergo positive and negative 
selection. Positive selection refers to when T-cells that adequately recognize 
self-peptide self-MHC complex are chosen for further differentiation, while 
negative selection is when self-recognizing autoimmune T-cells are signaled to 
die. Alloreactivity refers to when the T-cells can recognize peptide and 
allogeneic MHC complexes that were not encountered during thymic selection 
(10). Alloreactive T-cells have been widely studied in the context of GvHD and 
whether their elimination could reduce incidence of GvHD (21). However, 
alloreactivity is important for development of both, GvHD and GvL effect , in 
allogeneic HSCT (22). In a HLA-matched HSCT, alloantigens that mediate GvHD 
and GvL are called minor histocompatibility antigens (miHA). MiHAs are cell -
surface proteins that are associated with MHCs. Single nucleotide 
polymorphisms (SNPs) can translate into differences in miHAs between HLA-
matched donor-host pair, especially matched unrelated donors, and are 
increasingly being recognized for their therapeutic potential in leukemia (23, 24). 
However, whether miHA differences translate into graft versus host disease is 
debatable (25).  
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1.2.3 Existing Therapies for Graft Versus Host Disease 
One of the crucial aspects of therapeutic development for GvHD is 
preserving the GvL effect of the allogeneic HSCT. One of the widely-employed 
preventive therapies is reducing the intensity of myeloablative conditioning 
regimen given to the patient. While reduced intensity conditioning regimen 
considerably reduces GvHD symptoms, it also increases the burden on the donor 
HSCs for eliminating leukemia. Multiple studies have shown that reduced 
intensity conditioning fails to improve long-term survival due to high rate of 
leukemia relapse (17, 26). Another important step in development of GvHD is 
homing of T-cells to the site of tissue damage via chemokine signaling. Targeting 
alloreactive T-cell homing via chemokine-ligand antagonists such as CCR5 
antagonists, have shown to lessen the damage to the target organs (27). 
However, these therapies may also interfere with recruitment of 
immunosuppressive T-cell subsets (17, 28). Th-1, Th-2, and Th-17 type 
cytokines play variable and important roles in GvHD development. Cytokine 
modulators such as Alpha-1 antitrypsin and cytokine IL-22 are currently under 
clinical trials as therapy for their protective role in GvHD (29). Many other 
cytokines, such as IFNγ, TNF, IL-6, and IL-23 or their modulators are being 
studied using murine models of GvHD (17, 18). Additionally, JAK/STAT inhibitors 
have also shown promise as treatment therapy for GvHD (30). JAK-STAT 
signaling pathway is downstream of cytokine-receptor binding, and causes 
activation of antigen presenting cells (APCs), which in turn results in higher APC 
and T-cell interaction. Therefore, preventing donor APC activation by JAK/STAT 
inhibition could prevent GvHD without reducing the GvL activity. Lastly, there 
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has been increasing interest in immunomodulatory cell therapies for GvHD. 
Invariant Natural Killer T-cells (iNKT cells) (31), myeloid-derived suppressor 
cells (MDSCs) ((32, 33), and their various subsets, are being investigated in 
mouse models of GvHD for their immunosuppressive role through cytotoxic T-
cell interaction or production of immunosuppressive cytokines.  
These are few among a large number of therapies that are currently being 
studied for preventing GvHD development at various points in the signaling 
cascade. However, we wanted to determine the effect of blocking initial 
inflammation by using anti-inflammatory and anti-oxidative agent, and if it could 
stop the signaling cascade from progressing to GvHD related end organ damage 
and/or death.  
 1.3 Bilirubin Nanoparticle 
Bilirubin is a linear tetrapyrrole molecule, naturally found in human blood. 
It is an orange-yellow pigment, found in the liver and is produced as an end 
product of heme catabolism. At the end of a red blood cells’ (RBC) life time, they 
undergo lysis. In this process, hemoglobin gets degraded and the heme part gets  
oxidized by an enzyme called heme oxygenase, forming biliverdin. Biliverdin is 
a greenish molecule that gets reduced by an enzyme called biliverdin reductase  
(BVRA), to form bilirubin. This process occurs in the reticuloendothelial cells of 
the liver, spleen and bone marrow. This bilirubin is ultimately carried to the liver 
via blood, where it performs various biological functions. Bilirubin is  known for 
its anti-inflammatory and antioxidant properties and has been inversely 
correlated with cardiovascular risk (34). Bilirubin quenches reactive oxygen 
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species (ROS) and gets converted into biliverdin, which is converted back to 
bilirubin through BVRA enzyme ((35) Figure 1). This recycling property, makes 
bilirubin a very powerful protectant against cellular oxidative damage. Higher 
bilirubin levels in adults are correlated with a number of health benefits such as 
lower prevalence of, non-alcoholic fatty liver disease, cardiovascular disease 
development, colorectal cancer, and ischemia–reperfusion injury after liver 
transplantation among many others (36). 
 
 
 
 
 
 
 
Figure 1- Mechanism of production and anti-oxidative activity of Bilirubin 
(inspired from Bara an no et al. (35)). Heme part of the hemoglobin get oxidized 
to produce biliverdin, by an enzyme called heme oxygenase (HO) anchored on 
the endoplasmic reticulum (ER). With the help of an enzyme called biliverdin 
reductase (BVRA), biliverdin gets reduced to form bilirubin. BVRA regenerates 
bilirubin that gets oxidized to form biliverdin upon quenching of membrane bound 
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reactive oxygen species (ROS). This cycle enables low concentration bilirub in 
to quench up to 10,000 fold higher concentrations of oxidants.  
Despite its well-known anti-inflammatory and anti-oxidative properties 
Bilirubin is rendered difficult for clinical use because of its water  insolubility. In 
an attempt to harness the therapeutic properties of bilirubin, investigators at 
Korea Institute of Advanced Science and Technology (KIAST) South Korea, 
recently developed a water-soluble conjugate of bilirubin and polyethylene glycol  
(PEG), known as the bilirubin nanoparticle (BRNP). PEG forms a stable amide 
bond with bilirubin to form PEGylated bilirubin (PEG-BR). Since bilirubin is a 
lipophile and PEG is a hydrophile, the end product PEG-BR is an amphiphile, 
which self-assembles to form a micelle-like structure or bilirubin nanoparticle. 
This nanoparticle is about a 100 nm in size in freeze-dried state and retains the 
properties of bilirubin while being water-soluble. Upon stimulation with light, 
BRNP turns into photoisomer of bilirubin. Also and more importantly, upon 
oxidative stress such as with ROS, BRNP turns into biliverdin or oxidized 
fragments of bilirubin.  
Recent studies by investigators at KAIST, have shown that due to it’s free-
radical scavenging properties, BRNP selectively accumulates at the site of 
inflammation and tissue damage in dextran sodium sulfate induced colitis in 
murine model (37). In mice, pre-treated with BRNP, pathological changes 
associated with ischemic reperfusion were found to be significantly less as 
compared to mice that were treated with vehicle (38). Similarly, BRNP treatment 
showed significant benefits in mouse models of other inflammatory conditions, 
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such as asthma (39), pancreatic islet xenotransplantation (40), and even as a 
conjugate for anti-cancer therapy (41, 42). 
1.4 Hypothesis 
Therefore, we hypothesize that, BRNP treatment can reduce graft versus 
host disease due to its beneficial anti-inflammatory properties which act against 
tissue damage and inflammation in murine GvHD model.  
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Chapter 2- Materials and Methods 
2.1 Mice 
All animal experiments were conducted per The University of Texas MD 
Anderson Cancer Center’s Institutional Animal Care and Use Committee 
guidelines. Six- to eight- week old female, C57/B6J and Balb/c, mice were 
purchased from Jackson Laboratories (Bar Harbor, ME).  
2.2 Hematopoietic Stem Cell Transplantation 
On day 0, 10- to 15- week old female Balb/cJ mice were given 800 cGy of 
Total Body Irradiation (TBI). On Day 1, age-matched donor female C57/B6J mice 
were dissected to obtain spleen and hind limb bones (femurs and tibiae). 
Spleens were pooled together in sterile 1X PBS and gently mashed. The 
suspension was strained through a 70 μm cell strainer to obtain single cell 
suspension. Bone marrow cells were obtained by flushing the bones, with 1X 
PBS through a 27G needle, until they appeared white. Bone marrow cells were 
also similarly strained through 70 μm cell strainer to obtain a single cell 
suspension. Both, spleen and bone marrow lymphocytes (without red b lood 
cells) were counted on hemocytometer.  
For our first model, we transplanted 1 x 107 RBC lysed splenocytes in 
mice, while the negative control group received 5 x 10 6 BM cells only. These 
mice transplanted with splenocytes, either received a single dose of 10 mg/kg 
BRNP or equivalent volume of vehicle (1X PBS) on day 0.  
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For our second model, we transplanted 1 x 106 conventional T-cells (CD4+ 
and CD8+ T-cells or Tcons) along with 4 x 106 BM cells. Starting from day 0, 
these mice received 3 doses of 10 mg/kg BRNP or equivalent volume of vehicle 
(1X PBS), every two days.  The negative control mice received 4 x 106 BM cells 
only. Tcons were purified using MACS® Cell Separation technique (Miltenyi 
Biotec). For isolating CD4+ and CD8+ T-cells, 5 x 108 splenocytes from donor 
mice were incubated with anti-mouse CD4 MicroBeads (clone: L3T4, cat no. 130-
117-043) and anti-mouse CD8 MicroBeads (clone: Ly2, cat no. 130-117-044) in 
magnetic associated cell sorting (MACS) buffer (PBS, pH 7.2, 0.5% human 
serum albumin-HSA (Sigma Life Science, cat. no. SRP6182)), and 2 mM EDTA 
(USB- Thermo Fisher, cat. no. 15694) for 20 minutes in dark at room 
temperature. Subsequently, CD4+ and CD8+ T-cells were isolated using LS 
column (Miltenyi Biotec, cat. no. 130-052-401) according to the manufacturer’s 
specified protocol. The isolated Tcons were washed and resuspended in 1X PBS 
for counting and subsequent transplantation in mice.  
For our third model, 5 x 106 splenocytes and 5 x 106 bone marrow cells 
were transplanted intravenously. The negative control group received 5 x 106 
bone marrow cells only. From day 0 to day 4, mice received 5 daily doses of 10 
mg/kg BRNP or equivalent volume of vehicle (1X PBS) intravenously.  
2.3 Bilirubin Nanoparticle 
Lyophilized BRNP was generously provided by Dr. Sangyong Jon and his 
laboratory at the Korea Advanced Institute of Science and Technology (KAIST), 
South Korea. Five milligrams of lyophilized BRNP was dissolved in 1 ml of 1X 
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PBS. This solution was stored at 4oC, protected from light, and used within 7 
days.  
2.4 Flow Cytometry Analysis 
Splenocytes and bone marrow cells that were used for transplant, were 
stained with anti-mouse, CD3ε (BioLegend, cat no. 100306), B220 (BD 
Pharmingen™, cat no. 553093), CD4 (BD Pharmingen™, cat no. 558107), and 
CD8 (BD Horizon™, cat no. 563068) antibodies for 30 minutes in dark. The cells 
were then washed with 1X PBS, fixed in 2% paraformaldehyde, and stored at 
4oC until flow acquisition. The samples were acquired using Canto II Cell 
Analyzer (Beckton, Dickinson and Company, Franklin Lakes, NJ), and FlowJo 
version 10.3 (Tree Star, Ashland, OR) was used for analysis. 
2.5 Clinical Graft Versus Host Disease Assessment 
Mice were scored for clinical GvHD, by using a previously established 
scoring system by Cooke et al.(43). Mice were scored from 0-2 for, Weight (0: 
<10% loss, 1: ≥10% <25%, 2: ≥25%), Fur (0: normal, 1: mild to moderate, 2: 
severe ruffling), Posture (0: normal, 1: kyphosis at rest, 2: kyphosis impairing 
movement), Activity (0: normal, 1: stationary 50% of the t ime, 2: stationary 
unless stimulated), Skin (0: normal, 1: scaling paws or tails, 2: lesions). In 
addition, all the treatment groups were also monitored for survival, and sacrificed 
if they seemed inactive or non-responsive to stimuli. 
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2.6 Pathological Graft Versus Host Disease 
On day 0, 10-15 week old female Balb/c mice received 800 cGy TBI. On 
day 1, the donor C57/B6 mice were sacrificed to obtain their splenocytes and 
BM cells. 5 x 106 whole splenocytes and 5 x 106 bone marrow cells were 
transplanted intravenously to the BRNP treated and the vehicle groups. The 
negative control group received 5 x 106 bone marrow cells only. From day 0 (4 
hours after transplantation) to day 4, the mice received 5 daily doses of 10 mg/kg 
BRNP or equivalent volume of vehicle (1X PBS) intravenously. These mice were 
sacrificed on day 8 after transplantation, and their blood, spleen, liver, lung, and 
skin were harvested for other downstream exper iments- serum cytokine analysis 
and histopathology.  
2.7 Serum Cytokine Quantification 
Blood for each individual mouse was collected by retro-orbital vein 
puncture. Tubes with blood were centrifuged at 600g for 5 minutes. Serum 
supernatant was collected and stored at -80oC until used for analysis. BD™ 
Cytometric Bead Array (CBA) (cat no. 560485) was used to determine the serum 
cytokine concentrations of Th1, Th2, and Th17 type cytokines, namely- IL2, IL-
4, IL-6, IFN-γ, TNF, IL-17A, and IL-10 proteins. Sera for all the treatment group 
mice was diluted 1:4 in assay diluent, incubated with mixed capture beads and 
subsequently washed according to the manufacturer’s instructions. The samples 
were acquired using LSR Fortessa Cell Analyzer (Beckton, Dickinson and 
Company, Franklin Lakes, NJ), and FlowJo version 10.3 (Tree Star, Ashland, 
OR) was used for analysis. 
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2.8 Histopathology  
Mouse organs, namely- skin (from dorsal region), liver (one lobe), lung 
(one lobe), small intestine (duodenum), and spleen, were fixed in 10% buffered 
formalin, and submitted to Research Histology Core Laboratory at The University 
of Texas MD Anderson Cancer Center, for haematoxylin and eosin staining. The 
sample slides were then evaluated by a pathologist who scored the tissues for 
inflammation and GvHD associated damage for each organ.  
2.9 Statistical Analysis 
All statistical analyses were performed using GraphPad Prism Software 
version 7.00 (La Jolla, California) for Windows. Data sets were analyzed using 
Mann-Whitney U Test with confidence level: 95%, and p values for comparisons 
between groups were determined. For survival analysis, Log-rank (Mantel-Cox) 
survival test was used. A p value less than 0.05 was considered to be statistically 
significant. 
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Chapter 3- Results and Analysis 
3.1 Mouse Model of Graft Versus Host Disease 
The first step to determine the anti-inflammatory and anti-oxidative effects 
of BRNP, was to establish a simple and reproducible murine model for acute 
GvHD. We chose HLA mismatch model of H-2b C57BL/6 mice as donors and H-
2d Balb/c mice as recipients. To determine optimal transplant dose, we 
shortlisted different published models with their respective outcomes, as 
outlined in Table 1 below.  
Table 1- Shortlist of published murine GvHD models- detailed for their 
transplant dose, radiation dose, and outcome 
 
HLA Mismatch model- C57BL6 (H2
b
) → Balb/c (H2
d
) 
Cell type and 
dose 
Conditioning 
Regimen 
Outcome Reference  
2 x 10
7
 Whole 
Splenocytes 
700 cGy Survival between 
day 10-50 
Margalit et al.(44) 
5 x 10
6
 TCD-BM 
and 1 x 10
6
 Tcons 
2 doses of 
400 cGy 
Systemic 
disease by Day 
7-30 
Schneidawind et al. 
(31) and Griesenauer 
et al. (45) 
5 x 10
6
 BM and 5 
x 10
6
 Splenocytes 
800 cGy Survival between 
day 10-40 
Im et al. (46) and 
Wang et al.(47)  
25 x 10
6
 GM-CSF 
mobilized 
splenocytes  
900 cGy Systemic 
disease by day 
5-14 
Kuns et al. (48) 
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We attempted three models with or without BRNP treatment. The first 
murine model (Margalit et al. (44); Table 1) received 800 cGy radiation on day 
0, and a single dose of 10 mg/kg BRNP (optimized by our collaborating 
investigators (38)) 4 hours after radiation (Figure 2a). On day 1, the vehicle 
control (n=10) and the BRNP test group (n=10) of mice were transplanted with 
1 x 107 RBC lysed splenocytes and 5 x 106 BM cells, whereas the negative 
control group (n=5) received 5 x 106 BM cells only. Mice were monitored for their 
weight and GvHD score every two days or until their death/ recommended 
euthanasia. Euthanasia was recommended at very low or no activity and/or 
extreme (>30%) weight loss.  
The mice in this experimental group were highly inactive and lost more 
than 25% of their initial weight within 8 days from transplantation (Figure 2b). 
We observed that mice were severely kyphotic and lethargic, owing to the high 
dose of RBC lysed splenocytes (Figure 2c). Within 13 days, 100% of both the 
vehicle control and the BRNP test groups had died (Figure 2d). For our next 
experiment, we concluded that, donor cell dose should be lowered and BRNP 
dose should be increased. 
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Figure 2- Clinical GvHD outcome of the first strategy of murine GvHD 
model. (A)- Vehicle control group (n=10), BRNP test group (n=10) and negative 
control group (n=5) received 800 cGy TBI on day 0. On day 1, vehicle control 
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group and BRNP treated group were transplanted with 1 x 107 RBC lysed 
splenocytes, while the negative control group was transplanted with 5 x 106 BM 
cells only. BRNP test group received a single dose of 10 mg/kg, 4 hours after 
TBI on day 0, while the vehicle control group received vehicle (1X PBS) I.V. 
injection. There were no significant differences between the BRNP + BM Cells + 
Splenocytes (test) group versus the BM Cells + Splenocytes (vehicle) group in 
terms of (B)- weight change, (C)- GvHD score, and (D)- Survival. “ns” stands for 
non-significant. p value was determined using Mann Whitney U Test for weight 
and GvHD score, and Mantel Cox Survival Test for survival  
For our second strategy (Schneidawind et al. and Griesenauer et al. (31, 
45); Table 1), we performed TBI of 800 cGy on day 0, and 4 hours later the mice 
were given their first dose of 10 mg/kg BRNP or equivalent volume of vehicle 
(1XPBS). On day 1, the recipient mice were transplanted with 1 x 10 6 
conventional T-cells (Tcons) instead of whole splenocytes, along with 4 x 106 
BM cells. On day 2 and day 4, the mice received additional dose of 10 mg/kg 
BRNP or equivalent volume of vehicle (1XPBS) (Figure 3a). All the treatment 
groups were monitored for their weight, GvHD score, and survival, f or 2 months 
or until, their death/recommended euthanasia. Despite no significant  change in 
weight loss (Figure 3b), this experiment was successful as we observed 
significantly lower clinical GvHD scores in the BRNP treated group (Figure 3c) 
which translated into significantly better survival outcome (F igure 3d). 
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Figure 3- Clinical GvHD outcome of the second strategy of murine GvHD 
model. (A)- Vehicle group (n=9) and the BRNP treated group (n=9) mice were 
given 800 cGy TBI on day 0, and transplanted with 1 x 10 6 Tcons and 4 x 106 
BM cells from C57/B6 mice on day 1. On day 0, 2, and 4, the BRNP treated 
group mice were i.v. treated with 10 mg/kg dose of BRNP, while the vehicle 
control group received equivalent volume of 1X PBS. The negative control group 
(n=5) mice received 4 x 106 BM cells only. No significant changes between the 
BRNP + BM Cells + Splenocytes and BM Cells + Splenocytes groups were seen 
in (B)- Weight, however, BRNP + BM Cells + Splenocytes group of mice has 
significantly lower (C) GvHD score (p<0.0001, Mann Whitney U Test), which 
translated into better (D) survival (p=0.0322; Mantel-Cox Survival Test). The 
median survival for BRNP test group at day 60 was 65% as compared with 
vehicle control in which only 11% of the mice survived. Error bars represent 
standard error of mean.  
In other studies by our collaborating investigators they have reported that 
doses as high as 150 mg/kg BRNP (15-fold higher than our current dose) are 
non-toxic to mice (10 mg/kg). Therefore for our next strategy, we decided to 
increase the number of BRNP injections in order to maximize the anti-
inflammatory and anti-oxidative activity against GvHD. While several factors 
such as radiation dose, donor recipient strains, and pathogens associated with 
colony influence the GvHD outcome, the most important factor is the T-cell 
dosage (49). To test the efficacy of BRNP as an anti-inflammatory molecule, we 
wanted to establish a rather simplified murine model with reliable GvHD 
outcome.   
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3.2 BRNP Treatment Can Increase Survival in Murine Acute Graft Versus Host 
Disease Model 
We tested the anti-inflammatory and anti-oxidative benefits of BRNP 
treatment in murine acute GvHD by using our third model  (Im et al. and Wang et 
al. (46, 47); Table 1), which was consistently reproducible. For our third strategy, 
we gave 800 cGy TBI to the recipient mice on day 0, followed by intravenous 
administered of 10 mg/kg BRNP, 4 hours later . On day 1, we transplanted 5 x 
106 whole splenocytes and 5 x 106 BM cells in the vehicle control and the BRNP 
test groups, whereas the negative control group was transplanted with 5 x 106 
BM cells only. BRNP test group mice were given 5 daily doses of 10 mg/kg 
intravenous BRNP from day 0-4 while the vehicle control group similarly received 
vehicle (1X PBS) injections (Figure 4a). 
Similar to our second strategy for HSCT, we observed that after an initial 
weight loss within the first week (Figure 4b) for all the three treatment groups, 
only the BRNP treated group and the negative control mice swiftly recovered. 
The vehicle control group continued to show faster weight loss till around day 
13 and a delayed recovery as compared with BRNP treated or the negative 
control groups. We observed that while the BRNP treated mice continued to 
maintain their weight between 90-100% of their initial weight, the vehicle control 
mice kept getting significantly worse (p=0.0001;  Mann Whitney U Test) after their 
initial recovery. Similar to the weight loss trend, we observed significantly lower 
GvHD score in BRNP treated mice as compared to the vehicle control group 
(p=0.0003, Mann Whitney U Test; Figure 4c). Despite being a subjective method 
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of scoring, GvHD score provides a crucial measurement of clinical GvHD 
development in mouse model. The initial peak in GvHD score at around day 15 
for vehicle control mice, can be partly attributed to weight loss due to gut toxicity 
caused by radiation treatment. The BRNP treated group, however, did not seem 
to develop a similar extent of radiation toxicity, as their GvHD score did not 
increase. Although the vehicle control mice did recover from the initial weight 
loss, they quickly started to show clinical symptoms again at around day 20. At 
the same time, the BRNP treated group also showed a slight increment in their 
GvHD score, but it was still less than their vehicle control counterparts. While 
the untreated mice, continued to show symptoms through their lifetime, the 
BRNP treated group, recovered around day 30, and did not show GvHD 
symptoms anymore. Lower GvHD score and weight loss, translated into 
significantly higher survival (p=0.0001; Log-rank (Mantel-Cox) survival test) in 
BRNP treated mice, as compared with the vehicle control mice (Figure 4d). At 
day 60, 100% of the BRNP treated mice had survived, while for the vehicle 
control group, only 20% of the mice survived.  
We observed that the survival of BRNP treated mice in our thi rd model of 
acute GvHD (Figure 4d; 100% mice survived until day 60), is better than their 
survival in second strategy (Figure 3d; 65% mice survived until day 60). This 
could be attributed to either change in the transplantation strategy, or to the 
increase in number of BRNP injections. However, in both the strategies, 11% 
and 20% of the vehicle control mice survived by day 60, indicating that both 
strategies were capable of forming similar extent of GvHD. Therefore, increasing 
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the dose of BRNP, may have led to the higher survival in BRNP test group, 
indicating the potential beneficial effects of BRNP against GvHD development.  
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Figure 4- Clinical GvHD outcome of the third strategy of murine GvHD 
model. Shown here is cumulative data from N=2 independent experiments. (A)- 
Vehicle control group (n=10) and the BRNP test group (n=10) mice were given 
800 cGy TBI on day 0, and transplanted with 5 x 106 BM cells and 5 x 106 
splenocytes from C57/B6 mice on day 1. On day 0 to 4, the BRNP test group 
mice were given 10 mg/kg intravenous dose of BRNP, while the vehicle control 
group received similar vehicle (1X PBS) injections. The negative control group 
(n=5) mice received 5 x 106 BM cells only. As compared with BM Cells + 
Splenocytes group, the BRNP + BM Cells + Splenocytes group showed 
significantly lower (B)- Weight loss (*p<0.0001, Mann Whitney U Test) (C) GvHD 
score (*p<0.0001, Mann Whitney U Test), which translated into better (D) 
survival (p=0.0003; Mantel-Cox Survival Test). Error bars represent standard 
error of mean. *p<0.0001 (Mann Whitney U Test) between BRNP + BM Cells + 
Splenocytes and BM Cells + Splenocytes groups. #p=0.0208 (Mann Whitney U 
Test) between BRNP + BM Cells + Splenocytes and BM Cells only groups. 
&p=0.0003 (Mantel-Cox Survival Test) between BRNP + BM Cells + Splenocytes 
and BM Cells + Splenocytes groups.  
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3.3 BRNP Treatment Can Reduce Pathological Symptoms of Acute Graft Versus 
Host Disease  
To determine the protective role of BRNP treatment on pathological 
symptoms of acute GvHD, we performed histopathological analyses on GvHD 
target organs such as the liver, lung, gastrointestinal tract (GI), and skin. We 
performed SCT on three treatment groups, with our previously optimized third 
strategy, and on day 8 we sacrificed the mice to collect their GvHD target organs 
along with blood and spleen.  
We performed cytokine bead array on blood sera collected from all the 
treatment group mice. Serum levels for pro-inflammatory cytokine IFNγ (Figure 
5a) and TNF (Figure 5b) were trending lower in the BRNP test mice (n=5) as 
compared to vehicle control mice (n=4), however they were not found to be 
significantly different. Higher serum levels of these pro-inflammatory cytokines 
are associated with higher organ damage which result in more severe onset of 
acute GvHD (18). We also analyzed other Th1, Th2, Th17 cytokines such as IL2, 
IL-4, IL-6, IL-17A, and IL-10. However, due to limitations in the cytokine bead 
array, values lower than 20 pg/ml are not accurately detectable. And therefore, 
we were unable to measure the serum cytokine levels of these proteins in our 
treatment groups.  
A previous GvHD study showed that, transplant engraftment in mice, with 
4 x 106 MHC-mismatch splenocytes after 800 cGy radiation, happens within 6 
days after transplant (50). Another study with different acute GvHD mouse model 
shows that histopathological changes are most apparent at around 7 days after 
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transplantation (compared between day 5, day 7, and day 21) (51). Indeed, 
within 24 hours after HSCT in mice, the donor T-cells migrate to secondary 
lymphoid organs for alloantigen priming before migrating to the GvHD target 
organs (49). Based on these studies, we justified sacrificing the three treatment 
groups, along with naïve control, on 8 th day after transplantation.  
Manifestation of skin inflammation and rash is one of the first symptoms 
of GvHD development after allogeneic transplantation. In agreement with our 
hypothesis, we observed significantly lower inflammatory cell infiltration in skin 
of the BRNP treated mice as compared with vehicle control (Figure 6, Figure 
7a). Lung and liver damage is one of the hallmarks of GvHD development. We 
observed significantly less inflammation in lung (Figure 6, Figure 7b) and liver 
(Figure 6, Figure 7c) in BRNP treated mice when compared with vehicle control 
mice. Lastly, the duodenum part of the gastrointestinal tract shows significantly 
lesser necrosis in BRNP treated mice as compared to the vehicle control (Figure 
6, Figure 7d), thus proving our hypothesis that BRNP treatment can reduce 
pathological symptoms of GvHD. 
Quantitative evaluation of GvHD associated organ damage shows 
significantly lower lymphocyte infiltration in hair follicles (Figure 7a; p=0.0079; 
Mann-Whitney Test) indicating lower skin damage in mice treated with BRNP. 
We also observed significantly lower perivascular inflammation in lung (Figure 
7b), and central vein inflammation in liver (Figure 7c). GI tract damage is one of 
the hallmarks of GvHD, and we found significantly lower single-cell necrosis in 
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the BRNP treated group as compared with vehicle control. BRNP treated mice 
showed close similarities with the negative control group in all histology scores.  
 
A          B 
 
 
 
 
 
Figure 5- Serum levels of pro-inflammatory cytokines IFNγ and TNFα. 
Cytokine analysis shows a trending decrease in pro-inflammatory cytokines (A)- 
IFNγ and (B)- TNF in the blood serum collected on day 8 post transplantation. 
Each dot represents individual mouse for all treatment groups.  The error bars 
represent standard deviation. ns= Non-significant (Mann- Whitney U Test).  
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Figure 6- BRNP treatment can reduce GvHD associated tissue damage, 
such as lymphocyte infiltration, inflammation, and necrosis.  Shown here are 
representative images of hematoxylin and eosin (H&E) staining for different 
GvHD target organs, namely, liver, lung, skin, and GI. Skin- In BM Cells + 
Splenocytes panel, green arrow shows an example of inflammatory cell 
infiltration, and the green arrow head shows an example of single-cell necrosis, 
which is significantly less in the BRNP treated mice. Lung- Donor (naïve control) 
and the BRNP treated mice show the least inflammation, as compared to the BM 
Cells + Splenocytes and BM Cells only group. Liver- Symbol P in the liver panel 
for all the treatment groups represents portal tract.  Compared with BM Cells + 
Splenocytes group, the BRNP treated mice show fewer inflammatory cells, while 
donor mouse shows normal portal vein with no inflammation. GI- Red arrows 
show single-cell necrosis in the glandular epithelium and the yellow asterisk (*) 
show necrotic cells in crypt lumen. BRNP treated mice showed lesser GI single-
cell necrosis as compared to BM Cells + Splenocytes group.  
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Figure 7- BRNP treatment can reduce pathological symptoms of acute 
GvHD in mice. Shown here is a quantitative evaluation of histopathology of 
acute GvHD performed by a board-certified pathologist. Pathological symptoms 
in different GvHD target organs such as (A) infiltration of hair follicles in skin, 
(B) perivascular inflammation, peribronchiolar inflammation, and interstitial 
pneumonia in lungs, (C) portal vein inflammation, central vein inflammation, and 
necrotic foci in liver, and (D) single cell necrosis and necrotic cells in crypt lumen 
of the GI. Histology ratio on y-axis for inflammatory conditions was measured by 
dividing the number of affected areas with total number of the areas observed 
under a 40X objective. Interstitial pneumonia scoring for lungs was done by 
evaluating the percentage of affected area under 10X objective and assigning a 
score from 1-4 with 4 being the most affected (Scoring: 1=<25%, 2=>25% to 
<50%, 3=>50% to <75%, 4=>75%). Similarly for liver, the number of necrotic foci 
counted were normalized with the number of evaluated areas observed under 
10X objective. Lastly, single cell necrosis or necrotic cells in crypt lumen for GI, 
were quantified by normalizing the counted number of necrotic cells with the 
number of areas evaluated. Dot-plots for all the treatment groups were plotted 
along with a single donor used as naïve histopathological control and statistics 
were performed using Mann-Whitney U Test.  
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Chapter 4- Discussion and Future Direction 
Most therapies such as steroids that are currently in clinic as first line 
treatment for GvHD are globally immunosuppressive, which leads to compromise 
in the GvL effect of the allogeneic HSCT. Other prophylactic therapies such as 
reduced conditioning regimen are good for reducing GvHD symptoms, however 
because of being non-myeloablative, it comes with a higher risk of infections 
and/or leukemia relapse (26). Several studies continue to explore and 
understand the immune cell interactions that happen after the allogeneic HSCT 
to identify potential therapeutic targets for GvHD. There have been a few studies 
that look at the role of anti-oxidative agents, such as hydrogen therapy (52), 
green tea extracts (53), and ROS scavenging compounds such as 
cyclopentylamino carboxymethylthiazolylindole (NecroX-7) (46) as treatment for 
GvHD related organ damage using murine models of GvHD. However, there is a 
critical unmet need for clinically relevant, scalable, and non-toxic therapies for 
GvHD that do not affect the GvL outcome. 
Bilirubin is a very effective and powerful antioxidant pigment found 
naturally in mammalian blood serum. Several human and mouse studies show 
that higher bilirubin level in blood serum is associated with protection against, 
cardiovascular diseases, non-alcoholic fatty liver disease, colorectal cancer, and 
ischemia–reperfusion injury after liver transplantation (36).  Bilirubin has shown 
to be an effective antioxidant immunomodulator as treatment for experimental 
autoimmune encephalomyelit is (54, 55). However, elevated blood serum levels 
of bilirubin can be toxic due to its water insolubility. Hyperbilirubinemia may 
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indicate liver damage and can be neurotoxic in new born infants. More 
importantly, elevated bilirubin levels are found in patients that develop acut e 
GvHD after allogeneic HSCT.  
To maximize the therapeutic potential and reduce the toxicity of bilirubin, 
investigators at KAIST conjugated polyethylene glycol with bilirubin, which 
resulted into an amphiphilic molecule that self-assembles to form stable, non-
toxic (at concentration as high as 150 mg/kg), and water soluble bilirubin 
nanoparticles. Polyethylene glycol is an FDA approved active ingredient . 
Conjugation with polyethylene glycol or PEGylation is used to improve the 
pharmacokinetic activity of various FDA approved drugs such as peginterferon 
alfa-2a for hepatitis C treatment (56). However, conjugation with PEG, especially 
near active site of the drug, may cause decrease in the drug activity in some 
cases (57). PEGylation of bilirubin has been shown to not affect the 
characteristic antioxidative and light sensitive properties of bilirubin, in both in 
vitro and in vivo experiments. Moreover, BRNP treatment has shown benefits in 
various mouse models of inflammatory diseases (37-41).  
In this study, we looked at clinical and pathological benefits of BRNP as 
a prophylactic therapy for GvHD. Through our pre-clinical mouse model of GvHD 
we show that five daily intravenous doses of 10 mg/kg BRNP treatment 
significantly reduces, GvHD symptoms, associated weight-loss, and improves 
overall survival. Pathological damage associated with the onset of GvHD was 
also found to be significantly less in skin, liver, lung, and GI. We found 
significantly lesser lymphocyte infiltration and inflammation in these organs , 
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which may have contributed to the higher overall survival. We believe that BRNP 
treatment was able to reduce the initial non-specific tissue damage associated 
with conditioning regimen and continued to reduce tissue damage after HSCT. 
Lower tissue damage could translate into reduced antigen presentation to donor 
cytotoxic T-cells, which ultimately lessens the cytokine production and end-
organ damage. We performed serum cytokine analysis, and saw a trend towards 
lower inflammatory cytokine production in the BRNP treated GvHD mice. Overall, 
our results show that prophylactic BRNP treatment in mouse GvHD model, is 
beneficial in reducing the symptoms and improving overall survival . 
In future studies, we want to assess a treatment model of BRNP in 
reducing GvHD symptoms and improving overall survival.  Through our mouse 
GvHD model, we plan to evaluate the role of post-transplantation BRNP 
treatment in alleviating GvHD symptoms without affecting the GVL activity of 
HSCT. In the treatment model, it  would also be interesting to analyze 
immunomodulatory effects of BRNP by performing flow cytometry analysis for 
various immune cells and subsets, on the GvHD target organs.  
Bilirubin nanoparticles dissociate into water-soluble photoisomers of 
bilirubin upon light (λ= 450 nm or 650 nm) stimulation (41). BRNP has also been 
shown to accumulate specifically at the site of tissue damage in a mouse colitis 
model, (37). Utilizing these properties of the nanoparticles, our collaborating 
investigators at KAIST, have successfully tested BRNP as a nano drug -carrier 
for anti-cancer therapy (42). Therefore, after establishing BRNP in a treatment 
model for GvHD, a future extension of this study would be to evaluate BRNP as 
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a drug conjugate for existing therapies for GvHD. Our first step would be to check 
for the accumulation site of the BRNP-drug conjugate in the mouse model, and 
test whether BRNP can successfully transport the drug to the site of organ 
damage. Eventually, we would compare clinical and pathological symptoms of 
GvHD along with overall survival using our mouse GvHD model treated with 
BRNP-drug conjugate and BRNP alone. Our hypothesis is that BRNP-drug 
conjugate can selectively reduce tissue damage, thereby reducing  the global 
toxicity of the drug and improving the GvHD outcome. 
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